Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockBearish
3
Neutral
7
Bullish
4
Bearish
13
Neutral
7
Bullish
26
Bearish
10
Neutral
0
Bullish
22
Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments.
The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency.
Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities.
Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins.
The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.
Pharmaceuticals & Biotechnology
Pharmaceuticals
75,122 Cr
Moderate Risk
84.5
34.1
3.6
14.2
1,457.00
640.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2382.00 | 97,948 Cr | 51.20 | 6.01 | 0.04 | 11.74 | 13.13 | 6.90 | ||
1462.65 | 85,035 Cr | 24.26 | 2.24 | 0.00 | 9.25 | 11.76 | 5.99 | ||
1393.00 | 75,122 Cr | 84.52 | 14.17 | 0.14 | 16.77 | 16.14 | 8.47 | ||
416.40 | 67,559 Cr | 175.21 | 1.99 | 0.12 | 1.14 | 3.64 | 0.58 | ||
5301.00 | 63,388 Cr | 27.54 | 4.59 | 1.00 | 16.66 | 18.61 | 11.27 | ||
2147.30 | 60,514 Cr | 44.44 | 5.76 | 0.12 | 28.08 | 32.70 | 6.84 | ||
26030.05 | 55,407 Cr | 35.70 | 11.61 | 1.82 | 32.51 | 42.54 | 23.87 | ||
| Median: 7 Co. | — | 2147.30 | 67,559 Cr | 44.44 | 5.76 | 0.12 | 16.66 | 16.14 | 6.90 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Laurus Labs Ltd (LAURUSLABS) is currently trading at 1,393.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Laurus Labs is a leading pharmaceutical and biotechnology company specializing in generic APIs and FDFs, with a strong focus on ARVs, oncology, and hepatitis treatments. The company achieved a remarkable 30% revenue growth, reaching ₹5,001 crore, driven by strong performance in its CDMO and Generics divisions, demonstrating robust operational efficiency. Significant capital investment occurred, with 15% of sales reinvested into expanding manufacturing capabilities, particularly in peptides and fermentation facilities. Laurus Labs reported an impressive 388% increase in net profit for 9M FY26, attributed to improved product mix and operational leverage, leading to expanded EBITDA and gross margins. The company is making strategic moves in biotechnology and advanced therapies, operationalizing gene therapy labs and actively investing in ADC capabilities, positioning itself in transformative health technologies.
Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹640.95 and a high of ₹1,457.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Laurus Labs Ltd has a market capitalization of approximately 75,121.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Laurus Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 84.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 75,121.70 Cr, Laurus Labs Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Laurus Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 84.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The dataset includes multiple snapshots, including ₹1,295.30 for 14 May 2026, and other updates showing ₹991.50 and ₹837.75 at different times.
The earnings conference call is scheduled for Thursday, April 30, 2026 at 5:00 PM IST.
Analyst consensus estimates Q4 FY26 revenue at Rs 1,620 crore, implying about 9% year-on-year growth.
The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay over five years, is the most significant announcement. It directly supports Laurus Labs' strategic investments in biologics, biosimilars, and its Bio division.
Sustainability report
Laurus Labs submitted its Business Responsibility & Sustainability Report (BRSR) for FY2025-26 on June 8, 2026 (standalone), with limited assurance by Deloitte Haskins & Sells LLP, noting exports of 62.14% and 7,059 employees.
AGM Notice
Notice of Laurus Labs' 21st AGM to be held July 2, 2026 via VC to consider adoption of audited standalone & consolidated FY2025‑26 financials, ratify interim dividends (Re.0.80 & Re.1.20), director appointments and other matters.
AGM Notice
Laurus Labs will hold its 21st Annual General Meeting on July 2, 2026 at 3:00 PM IST via VC/OAVM to approve FY2025‑26 audited standalone and consolidated financial statements, ratify two interim dividends, elect directors and pass other corporate resolutions; remote e‑voting runs June 29–July 1, 2026 (cut‑off June 25, 2026).
